Literature DB >> 25341589

Gynecologic Cancer InterGroup (GCIG) consensus review for cervical adenocarcinoma.

Hiroyuki Fujiwara1, Harushige Yokota, Bradley Monk, Isabelle Treilleux, Mojgan Devouassoux-Shisheboran, Alison Davis, Jae-Weon Kim, Sven Mahner, Michael Stany, Sandro Pignata, Isabelle Ray-Coquard, Keiichi Fujiwara.   

Abstract

Cervical adenocarcinoma is known to be less common than squamous cell carcinoma of the cervix comprising approximately 25% of all cervical carcinomas. Differences in associated human papillomavirus types, patterns of spread, and prognosis call for treatments that are not always like those for squamous cancers. In this review, we report a consensus developed by the Gynecologic Cancer InterGroup surrounding cervical adenocarcinoma for epidemiology, pathology, treatment, and unanswered questions. Prospective clinical trials are needed to help develop treatment guidelines.

Entities:  

Mesh：

Year:  2014        PMID： 25341589     DOI： 10.1097/IGC.0000000000000263

Source DB:  PubMed          Journal:  Int J Gynecol Cancer        ISSN： 1048-891X            Impact factor:   3.437


  20 in total

1.  CIP2A is associated with multidrug resistance in cervical adenocarcinoma by a P-glycoprotein pathway.

Authors:  Juan Liu; Meng Wang; Xiaoli Zhang; Qingwei Wang; Mei Qi; Jing Hu; Zhiqiang Zhou; Chunyan Zhang; Weifang Zhang; Weiming Zhao; Xiao Wang
Journal:  Tumour Biol       Date:  2015-09-24

Review 2.  The pattern is the issue: recent advances in adenocarcinoma of the uterine cervix.

Authors:  Andres A Roma; Oluwole Fadare
Journal:  Virchows Arch       Date:  2018-02-05       Impact factor: 4.064

Review 3.  Management of Stage IIB Cervical Cancer: an Overview of the Current Evidence.

Authors:  Shinya Matsuzaki; Maximilian Klar; Mikio Mikami; Muneaki Shimada; Brendan H Grubbs; Keiichi Fujiwara; Lynda D Roman; Koji Matsuo
Journal:  Curr Oncol Rep       Date:  2020-02-12       Impact factor: 5.075

4.  [Cervical cancer : Update on morphology].

Authors:  L-C Horn; C E Brambs; R Handzel; S Lax; I Sändig; D Schmidt; K Schierle
Journal:  Pathologe       Date:  2016-11       Impact factor: 1.011

5.  MRI-based radiomics for pretreatment prediction of response to concurrent chemoradiotherapy in locally advanced cervical squamous cell cancer.

Authors:  Xiaomiao Zhang; Qi Zhang; Xiaoduo Yu; Xinming Zhao; Yan Chen; Sicong Wang; Jieying Zhang; Jusheng An; Lizhi Xie
Journal:  Abdom Radiol (NY)       Date:  2022-10-12

6.  Is there different prognosis between cervical endometrioid adenocarcinoma and ordinary cervical adenocarcinoma in a propensity score matching study based on the surveillance, epidemiology, and end results (SEER) database?

Authors:  Fubin Zhang; Bohong Jin; Hui Yan; Tianhong Zhu; Huiqing Ding; Xueqin Chen; Yutao Guan
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

7.  High methylation of ZNF582 in cervical adenocarcinoma affects radiosensitivity and prognosis.

Authors:  Na-Yi Yuan Wu; Xiaoyun Zhang; Tangyuan Chu; Songlin Zhu; Yuping Deng; Yi Zhou; Ying Wang; Xueheng Zhao; Lu Liu; Chao Fang; Yang Wang; Yu-Ligh Liou; Jingting Cai; Jing Wang
Journal:  Ann Transl Med       Date:  2019-07

8.  Extrafascial hysterectomy after concurrent chemoradiotherapy in locally advanced cervical adenocarcinoma.

Authors:  Jie Yang; Keng Shen; Jinhui Wang; Jiaxin Yang; Dongyan Cao
Journal:  J Gynecol Oncol       Date:  2016-04-18       Impact factor: 4.401

9.  Ovarian preservation in adenocarcinoma of the uterine cervix.

Authors:  Jiansong Zhou; Yuanyuan Chen; Ping Zhang; Hanmei Lou
Journal:  J Ovarian Res       Date:  2017-07-24       Impact factor: 4.234

10.  Early-stage node negative cervical adenocarcinoma and squamous cell carcinoma show similar survival outcomes after hysterectomy: a population-based study.

Authors:  San Gang Wu; Jia Yuan Sun; Zhen Yu He; Qiong Hua Chen; Juan Zhou
Journal:  J Gynecol Oncol       Date:  2017-11       Impact factor: 4.401
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.